Photocat (PCAT) H2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
H2 2024 earnings summary
5 Jun, 2025Executive summary
Achieved positive EBITDA of 54,000 DKK in H2 2024 despite a 17% revenue decline compared to H2 2023, reflecting improved operational efficiency and cost control.
Secured a strategic licensing agreement with a major European company, strengthening bitumen IPR and expanding market reach.
Integrated bitumen technology into a Finnish facility and expanded the dust control portfolio via acquisition and partnership with Essity.
The Badalona project, the world's largest photocatalysis demonstration, continues to deliver strong environmental and economic results.
Financial highlights
H2 2024 revenue was 5.3 million DKK, down from 6.4 million DKK in H2 2023; FY 2024 revenue was 12.1 million DKK, down from 15.0 million DKK in FY 2023.
Gross profit for H2 2024 was 2.7 million DKK (vs. 3.0 million DKK in H2 2023); FY 2024 gross profit was 6.2 million DKK (vs. 6.3 million DKK in FY 2023).
EBITDA improved to 54,000 DKK in H2 2024 from -157,000 DKK in H2 2023; FY 2024 EBITDA was 743,000 DKK, up from 347,000 DKK in FY 2023.
Net loss widened to -2.2 million DKK in H2 2024 (vs. -1.3 million DKK in H2 2023); FY 2024 net loss was -2.6 million DKK (vs. -1.9 million DKK in FY 2023).
Cash at hand increased to 306,000 DKK at year-end 2024 (vs. 230,000 DKK at year-end 2023).
Outlook and guidance
2025 guidance projects revenue of 11.0–13.0 million DKK and positive EBITDA of 0.5–1.5 million DKK, indicating continued growth focus.
Over 55 specialized, recurrent customers and strong demand for sustainable solutions position the company for future expansion.
Latest events from Photocat
- Q4 and full-year profits rebounded on higher revenue, new products, and strategic partnerships.PCAT
H2 202518 Feb 2026 - Positive EBITDA and robust environmental impact achieved despite lower revenue and market headwinds.PCAT
H1 202520 Aug 2025 - Positive EBITDA and strategic Bitumen wins offset revenue decline; 2024 guidance reaffirmed.PCAT
H1 202413 Jun 2025